Navigation Links
VetStem Biopharma Enters Pet Cancer Field with Key License from Leading Human Cancer Company, Calidi Biotherapeutics
Date:7/19/2019

VetStem Biopharma has long been a leader in veterinary stem cell therapy with clinical, regulatory and manufacturing experience. As a result of a two-year research collaboration with Calidi Biotherapeutics, VetStem has signed a worldwide license and development agreement to commercialize the Calidi oncolytic virus platform in veterinary medicine. VetStem should be able to fast-track this cancer therapy for use in dogs due to the advanced stage of its own canine adipose stem cell program. In a patented process, Calidi has discovered how to utilize adipose stem cells as a “Trojan horse” to deliver their promising oncolytic virus therapy. This combination may substantially enhance the cancer-killing ability of the oncolytic virus.

VetStem is also an experienced FDA GMP cell therapy manufacturer. In addition to producing veterinary stem cells, VetStem has contracted with Calidi to provide them with human adipose stem cell lines for their clinical trial program. VetStem CEO, Dr. Robert Harman stated, “We believe that this One Medicine collaboration shows how closely allied human and veterinary medicine are and how together we can more rapidly develop and deliver products to both markets.”

Allan Camaisa, CEO of Calidi remarked, “We recognized early on in the collaboration that VetStem’s advanced manufacturing capability and experience with stem cell therapy could save an enormous amount of time and resources in the development of human stem cell lines for our program.”

VetStem has a broad portfolio of patents and applications in regenerative medicine and now with this license, has access to the Calidi portfolio of patents combining stem cells with oncolytic viruses.

“This is a unique opportunity in history to have a profound influence on the development and adoption of a potential game-changing medical technology,” says Dr. Harman. “Regenerative medicine has opened up new possible treatment options for a wide array of conditions that are not effectively treated with today’s medicines and now stem cells may play a key role in delivering cutting edge cancer therapy.”

VetStem is in the process of raising a final round of capital to complete its FDA-approved pivotal trial for canine osteoarthritis. The collaboration will allow very efficient use of these same stem cells for the newly-licensed cancer program.

About VetStem Biopharma, Inc.
VetStem Biopharma was formed in 2002 to advance regenerative medicine. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 15 years and 17,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The Company’s stated mission being “to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases”. In addition to its’ own portfolio of patents, VetStem holds exclusive global licenses to a portfolio of issued patents in the field of regenerative medicine.

Read the full story at https://www.prweb.com/releases/vetstem_biopharma_enters_pet_cancer_field_with_key_license_from_leading_human_cancer_company_calidi_biotherapeutics/prweb16446134.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. VetStem Biopharma is Pleased to Share the Success Story of Mandy, who was Treated with Stem Cell Therapy by Dr. Jerrold Bausman at VCA Vet Specialists of the Valley
2. Labrador Retriever Gets Back to Playing Fetch After Receiving VetStem Regenerative Stem Cell Therapy
3. VetStem Biopharma is Pleased to Share the Success Story of Sam Who was Treated with Stem Cell Therapy by Dr. Lucy Roberts at Animal Medical Center of Tuscaloosa
4. VetStem Biopharma is Pleased to Share the Success Story of Jack, a Great Pyrenees who was Treated with Stem Cell Therapy by Dr. Andrea Hayes
5. VetStem Biopharma Shares the Story of Anthony Who Came Back to Win Division Championship After Being Treated with Stem Cell Therapy by Dr. Ruth-Anne Richter
6. VetStem Biopharma Shares the Story of a Champion Horse Who Continues to Win After a Successful Stem Cell Treatment by Dr. John McCarroll
7. VetStem Biopharma is Pleased to Share the Success Story of Ava who was Treated with VetStem Cell Therapy by Dr. David Luck
8. VetStem Biopharma Shares the Success Story of Harper who was Treated with VetStem Cell Therapy by Dr. Christopher Eich
9. VetStem Biopharma Shares the Success Story of Seve who was Treated with VetStem Cell Therapy by Dr. Cindy Echevarria
10. Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection
11. Array BioPharma to Present at the NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2019)... and MARTINSRIED, Germany (PRWEB) , ... August 14, ... ... antibody screening and characterization, announced today that they have opened a Customer Experience ... has fueled the need for the new office. , The Munich CEC will ...
(Date:8/14/2019)... , ... August 14, 2019 , ... Representatives with MyBioGate ... and Exhibition Center in Boston. , “We help innovative projects connect with Chinese pharma ... for MyBioGate. , Guo went on to explain that as a part of Biotech ...
(Date:8/14/2019)... ... , ... Join Anguraj Sadanandam, PhD, Team Leader, Systems and ... in a live webinar on Wednesday, September 4, 2019 at 12pm ... development including machine learning approaches in different gastrointestinal cancers and their translational relevance. ...
Breaking Biology News(10 mins):
(Date:6/12/2019)... , ... June 12, 2019 , ... ... helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device and Food Packaging ... has been signed. The agreement will grant exclusive rights for Zillion to represent ...
(Date:6/11/2019)... CITY, Calif. (PRWEB) , ... June 10, 2019 ... ... (IOPP) today announced IOPP will add 80 of its scientific journals to DeepDyve’s ... of physics-related content to DeepDyve’s continually expanding library of more than 20 million ...
(Date:6/11/2019)... DURHAM, N.C. (PRWEB) , ... June 11, 2019 ... ... how extracellular vesicles derived from human mesenchymal stem cells (MSC-EV) are able to ... and cloning ability. In a test on mice, MSC-EVs also increased the cells’ ...
(Date:5/31/2019)... ... May 29, 2019 , ... ... proprietary interest to our methodology, processes, and diagnostic techniques. The patent applications ... Somnology’s IP rights including our proprietary sleep scoring methodology. The approval and ...
Breaking Biology Technology: